Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gastrointestinal Dermatology Gynecology & Urology

UCB to pocket $1.5bn from generics business sale

This article was originally published in Scrip

Executive Summary

Belgian pharma group UCB is to sell its US specialty generics business Kremers Urban Pharmaceuticals (KU) for $1.525bn in cash. Private equity companies Advent International and Avista Capital Partners are acquiring the business; Avista healthcare industry executive Brian Markison will become president and CEO of KU, succeeding George Stevenson, who will leave. Mr Markison was previously CEO of Fougera Pharmaceuticals, a dermatology company that was spun off from Nycomed in 2011 and sold to Sandoz in 2012.

Table

View full table

Topics

Related Companies

Tags:
Gastrointestinal Dermatology Gynecology & Urology
Latest Headlines

BridgeBio Spins Out Cancer Arm With $200m Fundraise

Emergex Goes To Battle Against ‘The Nasties’

Finance Watch: Venture Rounds Trend Toward The High End

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

See All
UsernamePublicRestriction

Register

SC026864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By